Tags

Type your tag names separated by a space and hit enter

Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.
Clin Vaccine Immunol. 2015 Jun; 22(6):618-30.CV

Abstract

The conventional hemagglutinin (HA)- and neuraminidase (NA)-based influenza vaccines need to be updated most years and are ineffective if the glycoprotein HA of the vaccine strains is a mismatch with that of the epidemic strain. Universal vaccines targeting conserved viral components might provide cross-protection and thus complement and improve conventional vaccines. In this study, we generated DNA plasmids and recombinant vaccinia viruses expressing the conserved proteins nucleoprotein (NP), polymerase basic 1 (PB1), and matrix 1 (M1) from influenza virus strain A/Beijing/30/95 (H3N2). BALB/c mice were immunized intramuscularly with a single vaccine based on NP, PB1, or M1 alone or a combination vaccine based on all three antigens and were then challenged with lethal doses of the heterologous influenza virus strain A/PR/8/34 (H1N1). Vaccines based on NP, PB1, and M1 provided complete or partial protection against challenge with 1.7 50% lethal dose (LD50) of PR8 in mice. Of the three antigens, NP-based vaccines induced protection against 5 LD50 and 10 LD50 and thus exhibited the greatest protective effect. Universal influenza vaccines based on the combination of NP, PB1, and M1 induced a strong immune response and thus might be an alternative approach to addressing future influenza virus pandemics.

Authors+Show Affiliations

National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China Institute of Immunization and Prevention, Beijing Center for Disease Control and Prevention, Dong Cheng District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China.National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention (China CDC), Chang Ping District, Beijing, China ruanlicdc@163.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25834017

Citation

Wang, Wenling, et al. "Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza a Virus Vaccines in Mice." Clinical and Vaccine Immunology : CVI, vol. 22, no. 6, 2015, pp. 618-30.
Wang W, Li R, Deng Y, et al. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice. Clin Vaccine Immunol. 2015;22(6):618-30.
Wang, W., Li, R., Deng, Y., Lu, N., Chen, H., Meng, X., Wang, W., Wang, X., Yan, K., Qi, X., Zhang, X., Xin, W., Lu, Z., Li, X., Bian, T., Gao, Y., Tan, W., & Ruan, L. (2015). Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice. Clinical and Vaccine Immunology : CVI, 22(6), 618-30. https://doi.org/10.1128/CVI.00091-15
Wang W, et al. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza a Virus Vaccines in Mice. Clin Vaccine Immunol. 2015;22(6):618-30. PubMed PMID: 25834017.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice. AU - Wang,Wenling, AU - Li,Renqing, AU - Deng,Yao, AU - Lu,Ning, AU - Chen,Hong, AU - Meng,Xin, AU - Wang,Wen, AU - Wang,Xiuping, AU - Yan,Kexia, AU - Qi,Xiangrong, AU - Zhang,Xiangmin, AU - Xin,Wei, AU - Lu,Zhenhua, AU - Li,Xueren, AU - Bian,Tao, AU - Gao,Yingying, AU - Tan,Wenjie, AU - Ruan,Li, Y1 - 2015/04/01/ PY - 2015/02/24/received PY - 2015/03/27/accepted PY - 2015/4/3/entrez PY - 2015/4/3/pubmed PY - 2016/2/26/medline SP - 618 EP - 30 JF - Clinical and vaccine immunology : CVI JO - Clin Vaccine Immunol VL - 22 IS - 6 N2 - The conventional hemagglutinin (HA)- and neuraminidase (NA)-based influenza vaccines need to be updated most years and are ineffective if the glycoprotein HA of the vaccine strains is a mismatch with that of the epidemic strain. Universal vaccines targeting conserved viral components might provide cross-protection and thus complement and improve conventional vaccines. In this study, we generated DNA plasmids and recombinant vaccinia viruses expressing the conserved proteins nucleoprotein (NP), polymerase basic 1 (PB1), and matrix 1 (M1) from influenza virus strain A/Beijing/30/95 (H3N2). BALB/c mice were immunized intramuscularly with a single vaccine based on NP, PB1, or M1 alone or a combination vaccine based on all three antigens and were then challenged with lethal doses of the heterologous influenza virus strain A/PR/8/34 (H1N1). Vaccines based on NP, PB1, and M1 provided complete or partial protection against challenge with 1.7 50% lethal dose (LD50) of PR8 in mice. Of the three antigens, NP-based vaccines induced protection against 5 LD50 and 10 LD50 and thus exhibited the greatest protective effect. Universal influenza vaccines based on the combination of NP, PB1, and M1 induced a strong immune response and thus might be an alternative approach to addressing future influenza virus pandemics. SN - 1556-679X UR - https://www.unboundmedicine.com/medline/citation/25834017/Protective_Efficacy_of_the_Conserved_NP_PB1_and_M1_Proteins_as_Immunogens_in_DNA__and_Vaccinia_Virus_Based_Universal_Influenza_A_Virus_Vaccines_in_Mice_ L2 - http://cvi.asm.org/cgi/pmidlookup?view=long&pmid=25834017 DB - PRIME DP - Unbound Medicine ER -